FeesSafety
Pluang+

Celldex halts barzolvolimab development for atopic dermatitis after Phase 2 trial misses key goals

Company Fundamentals
19 Nov 2026, 23:01 WIB
GlobeNewsWire
View Source
Bearish
Celldex halts barzolvolimab development for atopic dermatitis after Phase 2 trial misses key goals

Celldex Therapeutics announced that its Phase 2 trial of barzolvolimab for moderate to severe atopic dermatitis did not meet primary or key secondary efficacy endpoints, leading to discontinuation of development for this indication. While the drug showed systemic mast cell depletion and a favorable safety profile, improvements in itch and eczema severity were insufficient. Celldex remains focused on barzolvolimab's potential in chronic spontaneous urticaria and other conditions, with a Biologics License Application planned for 2027 and ongoing Phase 3 trials in related diseases.

Celldex's Phase 2 study results for barzolvolimab in atopic dermatitis provide context for health sector performance on Pluang. For readers following health stocks, here is Pluang's market snapshot as of Nov 20, 2026 03:13 WIB: out of 150 priced health-sector US stocks, only 15 rose while 135 fell. ClearPoint Neuro Inc (CLPT) traded at USD 7.25 with a 5.97% decline and full buy-side order activity, contrasting with UnitedHealth Group Inc (UNH) at USD 330.08 down 5.67% with a longer typical hold time of 99 days and a 67% buy order activity, while Oscar Health Inc (OSCR) was priced at USD 26.01, down 5.66% with a 17-day hold time.

More News

Saputo plans $600M investment to expand high-growth dairy products, boosting future earnings.

Saputo plans $600M investment to expand high-growth dairy products, boosting future earnings.

Saputo Inc. announced a $600 million investment program to expand its manufacturing capacity in high-growth dairy categories such as cottage cheese, functional beverages, high-protein dairy products, and cream cheese. The phased investments will begi...

Company Fundamentals
Bullish
56 minutes ago
Saputo to invest $600M in high-growth dairy products, boosting capacity and future earnings.

Saputo to invest $600M in high-growth dairy products, boosting capacity and future earnings.

Saputo Inc. announced a $600 million strategic investment to expand production capacity in high-growth dairy categories such as cottage cheese, functional beverages, high-protein dairy products, and cream cheese. The investment aims to meet rising cu...

Company Fundamentals
Bullish
56 minutes ago
Saputo to invest $600M in expanding high-growth dairy products, boosting capacity and earnings by 2029.

Saputo to invest $600M in expanding high-growth dairy products, boosting capacity and earnings by 2029.

Saputo Inc. announced a $600 million investment plan to expand its manufacturing capacity in high-growth dairy categories such as cottage cheese, functional beverages, and cream cheese. The phased investments will begin in fiscal 2027 and are expecte...

Company Fundamentals
Bullish
56 minutes ago
Hoppn launches Similar Colors to recommend color-matched products on Shopify product pages.

Hoppn launches Similar Colors to recommend color-matched products on Shopify product pages.

Hoppn introduced Similar Colors, a new feature in its Infinite Color Search app for Shopify, which recommends products matching the color of the item a shopper is viewing. This no-code app block analyzes product images to provide visually coordinated...

Others
Bullish
56 minutes ago
Alphabet shares fall 3.46% amid Anthropic IPO and new Blue Origin partnership news

Alphabet shares fall 3.46% amid Anthropic IPO and new Blue Origin partnership news

Alphabet's stock dropped 3.46% to $272.66 following Anthropic's Nasdaq debut and an update on Google's partnership with Blue Origin for satellite launches. Investors are closely watching how AI-related valuation changes impact Alphabet's portfolio, e...

Bearish
57 minutes ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App